Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ENDRA Life Sciences Inc.

< Previous 1 2 Next >
Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Announces Reverse Stock Split
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Announces Leadership Changes
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Provides Update Following In-person Meeting with FDA
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Installs First TAEUS System in the UK
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA
From ENDRA Life Sciences Inc.
Via Business Wire
Tickers NDRA
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.